Conference on Drug Against Tropical Protozoan Parasites
热带原生动物寄生虫药物会议
基本信息
- 批准号:6439860
- 负责人:
- 金额:$ 2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-03-01 至 2003-02-28
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Diseases in humans caused by protozoa lead to suffering in hundreds of millions of people worldwide. We are approaching a time when the genomes of organisms responsible for diseases such as malaria, sleeping sickness, and leishmaniasis are fully sequenced. This provides an optimal setting for the discovery and evaluation of new drug targets, especially when combined with structural biology, combinatorial chemistry, and parasite genetics. Effective drugs are lacking for diseases including sleeping sickness and leishmaniasis, and current therapies for treating malaria are at risk due to the emergence of drug resistance. Thus, the development of new lines of anti-protozoan agents is urgently needed. Strategies and approaches for the rational design of drugs against tropical protozoan parasites will be the main focus of our conference. Groups of talks, one or two given by the chemist/structural biologist and the other by the parasitologist will exemplify the power of multi- disciplinary collaborations. Industry has taken little interest in the development of drugs against tropical diseases. Most of the research in this area is done by graduate students who are planning to present posters at the conference. We consider the poster sessions that occur throughout our meeting to be just as important as the collection of lecture presentations.
由原生动物引起的人类疾病导致全世界数亿人遭受痛苦。 我们正在接近这样一个时刻,即疟疾、昏睡病和利什曼病等疾病的生物体基因组完全测序。这为发现和评估新的药物靶点提供了最佳环境,特别是当与结构生物学,组合化学和寄生虫遗传学相结合时。缺乏治疗昏睡病和利什曼病等疾病的有效药物,目前治疗疟疾的疗法由于出现耐药性而面临风险。因此,迫切需要开发新的抗原生动物剂。针对热带原生动物寄生虫的药物的合理设计的策略和方法将是我们会议的主要焦点。一组或两组由化学家/结构生物学家和寄生虫学家提供的讲座将展示多学科合作的力量。工业界对开发治疗热带疾病的药物兴趣不大。这一领域的大部分研究都是由计划在会议上展示海报的研究生完成的。我们认为在整个会议中出现的海报会议与演讲集一样重要。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael H Gelb其他文献
Therapeutic intervention based on protein prenylation and associated modifications
基于蛋白质异戊烯化及相关修饰的治疗干预
- DOI:
10.1038/nchembio818 - 发表时间:
2006-09-18 - 期刊:
- 影响因子:13.700
- 作者:
Michael H Gelb;Lucas Brunsveld;Christine A Hrycyna;Susan Michaelis;Fuyuhiko Tamanoi;Wesley C Van Voorhis;Herbert Waldmann - 通讯作者:
Herbert Waldmann
Michael H Gelb的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michael H Gelb', 18)}}的其他基金
Novel diagnostic biomarker reference standards for newborn screening of Mucopolysaccharidoses type I and II.
用于新生儿粘多糖病 I 型和 II 型筛查的新型诊断生物标志物参考标准。
- 批准号:
10757151 - 财政年份:2023
- 资助金额:
$ 2万 - 项目类别:
A tandem mass spectrometry diagnostic test for newborn screening of Tay-Sachs and Sandhoff diseases
用于新生儿泰萨克斯病和桑德霍夫病筛查的串联质谱诊断测试
- 批准号:
10484192 - 财政年份:2022
- 资助金额:
$ 2万 - 项目类别:
Biochemical Studies of 14 kDa Phospholipases A2
14 kDa 磷脂酶 A2 的生化研究
- 批准号:
6430660 - 财政年份:2002
- 资助金额:
$ 2万 - 项目类别:
Biochemical Studies of 14 kDa Phospholipases A2
14 kDa 磷脂酶 A2 的生化研究
- 批准号:
6621143 - 财政年份:2002
- 资助金额:
$ 2万 - 项目类别:
Biochemical Studies of 14 kDa Phospholipases A2
14 kDa 磷脂酶 A2 的生化研究
- 批准号:
7015023 - 财政年份:2002
- 资助金额:
$ 2万 - 项目类别:
Biochemical Studies of 14 kDa Phospholipases A2
14 kDa 磷脂酶 A2 的生化研究
- 批准号:
6703048 - 财政年份:2002
- 资助金额:
$ 2万 - 项目类别:
Biochemical Studies of 14 kDa Phospholipases A2
14 kDa 磷脂酶 A2 的生化研究
- 批准号:
6849331 - 财政年份:2002
- 资助金额:
$ 2万 - 项目类别:














{{item.name}}会员




